Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JORGE PAOLI-BRUNO

Allopathic & Osteopathic Physicians Family Medicine

NPI
1982601159
CMS profile
419826
Location
MEDLEY, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$120.40

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $120.40 1

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Allergan Inc. $120.40 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JORGE PAOLI-BRUNO

NPI 1982601159 · CMS profile ID 419826

Allopathic & Osteopathic Physicians / Family Medicine

MEDLEY, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1982601159?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JORGE PAOLI-BRUNO, NPI 1982601159, CMS profile ID 419826. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1982601159?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). JORGE PAOLI-BRUNO, NPI 1982601159, CMS profile ID 419826. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1982601159?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
JORGE PAOLI-BRUNO, NPI 1982601159, CMS profile ID 419826, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1982601159?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $120.40 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Allergan Inc. $120.4010/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670916157 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $120.40 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019
Generated from
OP_DTL_GNRL_PGYR2019_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

This record has limited reported data across the program years shown and is not featured in search indexes. The records below are complete; see the methodology for how featured pages are determined.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $961,612.31 249
PY2024 Recipient $4,214.80 1
PY2024 Principal investigator $2,148,310.31 277
PY2023 Principal investigator $1,000,560.67 172
PY2022 Recipient $253.00 2
PY2022 Principal investigator $730,831.67 34
PY2021 Recipient $1,654.33 2
PY2021 Principal investigator $437,077.46 64
PY2020 Recipient $2,885.98 3
PY2020 Principal investigator $359,635.45 60
PY2019 Principal investigator $605,972.33 74

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

249 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Bausch Health US, LLC $165.00 11/06/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838463
Principal investigator 1 Bausch Health US, LLC $165.00 11/06/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838467
Principal investigator 1 Bausch Health US, LLC $165.00 11/06/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838471
Principal investigator 1 Bausch Health US, LLC $1,400.00 11/06/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838479
Principal investigator 1 Bausch Health US, LLC $2,203.00 10/06/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838475
Principal investigator 1 Eli Lilly and Company $206.45 09/24/2025 Non-covered Recipient Entity
EZY MEDICAL RESEARCH CO
A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 No dispute reported 06/30/2026 1187882932
Principal investigator 1 Bausch Health US, LLC $1,756.00 09/03/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837605
Principal investigator 1 Bausch Health US, LLC $1,400.00 09/03/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837634
Principal investigator 1 Bausch Health US, LLC $1,400.00 09/03/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837688
Principal investigator 1 Bausch Health US, LLC $1,400.00 09/03/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837827
Principal investigator 1 Bausch Health US, LLC $1,400.00 09/03/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837907
Principal investigator 1 Bausch Health US, LLC $2,203.00 09/03/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838436
Principal investigator 1 Eli Lilly and Company $124.75 07/28/2025 Non-covered Recipient Entity
EZY MEDICAL RESEARCH CO
A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF GALCANEZUMAB IN ADOLESCENT PATIENTS 12 TO 17 YEARS OF AGE WITH CHRONIC MIGRAINE THE REBUILD 2 STUDY No dispute reported 06/30/2026 1187880946
Principal investigator 1 Bausch Health US, LLC $462.00 07/23/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837574
Principal investigator 1 Bausch Health US, LLC $2,203.00 07/23/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837581
Principal investigator 1 Bausch Health US, LLC $1,756.00 07/23/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837708
Principal investigator 1 Bausch Health US, LLC $2,203.00 07/23/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838151
Principal investigator 1 Bausch Health US, LLC $1,300.00 07/23/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838160
Principal investigator 1 Bausch Health US, LLC $2,203.00 07/23/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838204
Principal investigator 1 Bausch Health US, LLC $165.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837544
Principal investigator 1 Bausch Health US, LLC $1,974.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837547
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837551
Principal investigator 1 Bausch Health US, LLC $1,824.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837555
Principal investigator 1 Bausch Health US, LLC $1,974.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837560
Principal investigator 1 Bausch Health US, LLC $1,633.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837564
Principal investigator 1 Bausch Health US, LLC $1,702.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837567
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837577
Principal investigator 1 Bausch Health US, LLC $1,300.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837585
Principal investigator 1 Bausch Health US, LLC $1,633.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837587
Principal investigator 1 Bausch Health US, LLC $1,300.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837591
Principal investigator 1 Bausch Health US, LLC $1,633.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837595
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837599
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837610
Principal investigator 1 Bausch Health US, LLC $165.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837614
Principal investigator 1 Bausch Health US, LLC $1,300.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837618
Principal investigator 1 Bausch Health US, LLC $1,300.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837621
Principal investigator 1 Bausch Health US, LLC $1,300.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837626
Principal investigator 1 Bausch Health US, LLC $1,974.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837630
Principal investigator 1 Bausch Health US, LLC $1,300.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837638
Principal investigator 1 Bausch Health US, LLC $1,633.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837641
Principal investigator 1 Bausch Health US, LLC $1,300.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837645
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837649
Principal investigator 1 Bausch Health US, LLC $1,633.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837653
Principal investigator 1 Bausch Health US, LLC $1,824.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837656
Principal investigator 1 Bausch Health US, LLC $3,278.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837661
Principal investigator 1 Bausch Health US, LLC $1,300.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837664
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837669
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837673
Principal investigator 1 Bausch Health US, LLC $1,300.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837676
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837680
Principal investigator 1 Bausch Health US, LLC $1,633.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837684
Principal investigator 1 Bausch Health US, LLC $3,278.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837691
Principal investigator 1 Bausch Health US, LLC $1,756.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837695
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837699
Principal investigator 1 Bausch Health US, LLC $1,824.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837704
Principal investigator 1 Bausch Health US, LLC $165.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837713
Principal investigator 1 Bausch Health US, LLC $1,633.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837717
Principal investigator 1 Bausch Health US, LLC $1,702.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837722
Principal investigator 1 Bausch Health US, LLC $165.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837725
Principal investigator 1 Bausch Health US, LLC $3,278.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837729
Principal investigator 1 Bausch Health US, LLC $1,633.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837732
Principal investigator 1 Bausch Health US, LLC $3,278.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837737
Principal investigator 1 Bausch Health US, LLC $1,633.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837741
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837746
Principal investigator 1 Bausch Health US, LLC $1,756.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837750
Principal investigator 1 Bausch Health US, LLC $1,300.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837754
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837759
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837763
Principal investigator 1 Bausch Health US, LLC $1,702.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837767
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837770
Principal investigator 1 Bausch Health US, LLC $3,278.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837774
Principal investigator 1 Bausch Health US, LLC $1,702.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837778
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837782
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837786
Principal investigator 1 Bausch Health US, LLC $1,756.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837790
Principal investigator 1 Bausch Health US, LLC $1,756.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837795
Principal investigator 1 Bausch Health US, LLC $165.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837800
Principal investigator 1 Bausch Health US, LLC $1,702.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837803
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837805
Principal investigator 1 Bausch Health US, LLC $1,300.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837810
Principal investigator 1 Bausch Health US, LLC $3,278.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837814
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837819
Principal investigator 1 Bausch Health US, LLC $1,300.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837824
Principal investigator 1 Bausch Health US, LLC $1,702.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837832
Principal investigator 1 Bausch Health US, LLC $1,300.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837835
Principal investigator 1 Bausch Health US, LLC $1,633.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837841
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837846
Principal investigator 1 Bausch Health US, LLC $1,974.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837850
Principal investigator 1 Bausch Health US, LLC $1,633.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837854
Principal investigator 1 Bausch Health US, LLC $1,756.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837858
Principal investigator 1 Bausch Health US, LLC $1,756.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837861
Principal investigator 1 Bausch Health US, LLC $165.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837865
Principal investigator 1 Bausch Health US, LLC $1,974.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837868
Principal investigator 1 Bausch Health US, LLC $1,756.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837871
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837876
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837880
Principal investigator 1 Bausch Health US, LLC $1,633.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837884
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837888
Principal investigator 1 Bausch Health US, LLC $1,633.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837891
Principal investigator 1 Bausch Health US, LLC $1,974.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837894
Principal investigator 1 Bausch Health US, LLC $1,633.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837899
Principal investigator 1 Bausch Health US, LLC $1,633.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837903
Principal investigator 1 Bausch Health US, LLC $1,300.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837911
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837915
Principal investigator 1 Bausch Health US, LLC $1,300.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837920
Principal investigator 1 Bausch Health US, LLC $1,300.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837924
Principal investigator 1 Bausch Health US, LLC $1,633.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837928
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837932
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837935
Principal investigator 1 Bausch Health US, LLC $1,702.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837939
Principal investigator 1 Bausch Health US, LLC $1,300.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837944
Principal investigator 1 Bausch Health US, LLC $1,702.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837948
Principal investigator 1 Bausch Health US, LLC $1,633.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837951
Principal investigator 1 Bausch Health US, LLC $1,633.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837957
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837961
Principal investigator 1 Bausch Health US, LLC $1,633.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837965
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837970
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837974
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837978
Principal investigator 1 Bausch Health US, LLC $2,203.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837981
Principal investigator 1 Bausch Health US, LLC $3,278.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837985
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837988
Principal investigator 1 Bausch Health US, LLC $1,300.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837993
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224837997
Principal investigator 1 Bausch Health US, LLC $1,400.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838002
Principal investigator 1 Bausch Health US, LLC $1,756.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838006
Principal investigator 1 Bausch Health US, LLC $1,633.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838009
Principal investigator 1 Bausch Health US, LLC $1,702.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838013
Principal investigator 1 Bausch Health US, LLC $1,702.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838017
Principal investigator 1 Bausch Health US, LLC $165.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838022
Principal investigator 1 Bausch Health US, LLC $1,756.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838026
Principal investigator 1 Bausch Health US, LLC $1,824.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838030
Principal investigator 1 Bausch Health US, LLC $1,756.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838033
Principal investigator 1 Bausch Health US, LLC $1,633.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838037
Principal investigator 1 Bausch Health US, LLC $1,300.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838042
Principal investigator 1 Bausch Health US, LLC $165.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838046
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838050
Principal investigator 1 Bausch Health US, LLC $1,400.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838052
Principal investigator 1 Bausch Health US, LLC $1,756.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838056
Principal investigator 1 Bausch Health US, LLC $1,702.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838059
Principal investigator 1 Bausch Health US, LLC $1,702.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838064
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838068
Principal investigator 1 Bausch Health US, LLC $1,633.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838071
Principal investigator 1 Bausch Health US, LLC $1,633.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838076
Principal investigator 1 Bausch Health US, LLC $2,203.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838079
Principal investigator 1 Bausch Health US, LLC $1,300.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838082
Principal investigator 1 Bausch Health US, LLC $1,300.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838085
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838090
Principal investigator 1 Bausch Health US, LLC $1,702.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838094
Principal investigator 1 Bausch Health US, LLC $1,756.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838098
Principal investigator 1 Bausch Health US, LLC $1,633.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838101
Principal investigator 1 Bausch Health US, LLC $3,278.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838105
Principal investigator 1 Bausch Health US, LLC $1,756.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838107
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838112
Principal investigator 1 Bausch Health US, LLC $1,974.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838116
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838120
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838125
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838130
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838133
Principal investigator 1 Bausch Health US, LLC $1,974.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838137
Principal investigator 1 Bausch Health US, LLC $1,633.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838139
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838143
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838147
Principal investigator 1 Bausch Health US, LLC $1,300.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838154
Principal investigator 1 Bausch Health US, LLC $1,702.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838156
Principal investigator 1 Bausch Health US, LLC $1,300.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838162
Principal investigator 1 Bausch Health US, LLC $165.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838165
Principal investigator 1 Bausch Health US, LLC $1,300.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838170
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838174
Principal investigator 1 Bausch Health US, LLC $1,633.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838178
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838182
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838186
Principal investigator 1 Bausch Health US, LLC $1,702.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838189
Principal investigator 1 Bausch Health US, LLC $1,300.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838193
Principal investigator 1 Bausch Health US, LLC $1,702.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838197
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838201
Principal investigator 1 Bausch Health US, LLC $1,702.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838209
Principal investigator 1 Bausch Health US, LLC $1,300.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838213
Principal investigator 1 Bausch Health US, LLC $2,203.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838216
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838220
Principal investigator 1 Bausch Health US, LLC $1,974.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838224
Principal investigator 1 Bausch Health US, LLC $1,633.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838228
Principal investigator 1 Bausch Health US, LLC $1,633.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838231
Principal investigator 1 Bausch Health US, LLC $1,400.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838235
Principal investigator 1 Bausch Health US, LLC $1,702.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838238
Principal investigator 1 Bausch Health US, LLC $1,756.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838243
Principal investigator 1 Bausch Health US, LLC $1,702.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838247
Principal investigator 1 Bausch Health US, LLC $1,300.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838250
Principal investigator 1 Bausch Health US, LLC $1,633.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838253
Principal investigator 1 Bausch Health US, LLC $1,300.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838259
Principal investigator 1 Bausch Health US, LLC $3,278.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838262
Principal investigator 1 Bausch Health US, LLC $1,974.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838266
Principal investigator 1 Bausch Health US, LLC $2,203.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838270
Principal investigator 1 Bausch Health US, LLC $1,824.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838273
Principal investigator 1 Bausch Health US, LLC $165.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838277
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838282
Principal investigator 1 Bausch Health US, LLC $1,633.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838286
Principal investigator 1 Bausch Health US, LLC $1,702.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838289
Principal investigator 1 Bausch Health US, LLC $3,278.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838293
Principal investigator 1 Bausch Health US, LLC $1,756.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838299
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838302
Principal investigator 1 Bausch Health US, LLC $1,300.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838304
Principal investigator 1 Bausch Health US, LLC $3,278.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838309
Principal investigator 1 Bausch Health US, LLC $3,278.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838313
Principal investigator 1 Bausch Health US, LLC $165.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838317
Principal investigator 1 Bausch Health US, LLC $1,702.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838321
Principal investigator 1 Bausch Health US, LLC $1,300.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838326
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838330
Principal investigator 1 Bausch Health US, LLC $1,300.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838335
Principal investigator 1 Bausch Health US, LLC $1,702.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838339
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838344
Principal investigator 1 Bausch Health US, LLC $165.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838348
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838352
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838356
Principal investigator 1 Bausch Health US, LLC $1,633.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838360
Principal investigator 1 Bausch Health US, LLC $1,633.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838364
Principal investigator 1 Bausch Health US, LLC $1,824.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838369
Principal investigator 1 Bausch Health US, LLC $1,824.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838372
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838377
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838381
Principal investigator 1 Bausch Health US, LLC $1,633.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838383
Principal investigator 1 Bausch Health US, LLC $3,278.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838387
Principal investigator 1 Bausch Health US, LLC $1,702.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838391
Principal investigator 1 Bausch Health US, LLC $1,300.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838395
Principal investigator 1 Bausch Health US, LLC $1,756.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838398
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838403
Principal investigator 1 Bausch Health US, LLC $1,702.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838407
Principal investigator 1 Bausch Health US, LLC $165.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838410
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838413
Principal investigator 1 Bausch Health US, LLC $1,300.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838417
Principal investigator 1 Bausch Health US, LLC $1,974.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838422
Principal investigator 1 Bausch Health US, LLC $1,300.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838426
Principal investigator 1 Bausch Health US, LLC $1,824.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838429
Principal investigator 1 Bausch Health US, LLC $462.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838433
Principal investigator 1 Bausch Health US, LLC $1,300.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838440
Principal investigator 1 Bausch Health US, LLC $1,300.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838443
Principal investigator 1 Bausch Health US, LLC $1,300.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838448
Principal investigator 1 Bausch Health US, LLC $1,702.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838454
Principal investigator 1 Bausch Health US, LLC $1,702.00 07/07/2025 Non-covered Recipient Entity
Coral Research Clinic Corp.
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224838458
Principal investigator 1 IBSA Institut Biochimique SA $12,952.50 05/27/2025 Non-covered Recipient Entity
PCRS NETWORK LLC
A multi-center, prospective, randomized, double-blind, flexible-dose, placebo-controlled, parallel group clinical trial of Sildenafil oral film 25 mg, 50 mg, 75 mg and 100 mg for the treatment of erectile dysfunction (ED) No dispute reported 06/30/2026 1223438837
Principal investigator 1 IBSA Institut Biochimique SA $12,348.20 04/29/2025 Non-covered Recipient Entity
PCRS NETWORK LLC
A multi-center, prospective, randomized, double-blind, flexible-dose, placebo-controlled, parallel group clinical trial of Sildenafil oral film 25 mg, 50 mg, 75 mg and 100 mg for the treatment of erectile dysfunction (ED) No dispute reported 06/30/2026 1223439049
Principal investigator 1 GlaxoSmithKline, LLC. $8,820.00 04/04/2025 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192186517
Principal investigator 1 Eli Lilly and Company $1,094.61 01/31/2025 Non-covered Recipient Entity
EZY MEDICAL RESEARCH CO
PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 No dispute reported 06/30/2026 1187880944
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $349,167.96 01/29/2025 Non-covered Recipient Entity
Coral Research Clinic Corporation
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Relapse Prevention Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease No dispute reported 06/30/2026 1235997830
Principal investigator 1 Eli Lilly and Company $1,462.84 01/27/2025 Non-covered Recipient Entity
EZY MEDICAL RESEARCH CO
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF GALCANEZUMAB IN PATIENTS 6 TO 17 YEARS OF AGE WITH EPISODIC MIGRAINE - THE REBUILD STUDY No dispute reported 06/30/2026 1187880069
Principal investigator 1 Eli Lilly and Company $39,464.00 01/21/2025 Non-covered Recipient Entity
EZY MEDICAL RESEARCH CO
A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 No dispute reported 06/30/2026 1187881160
Principal investigator 1 Eli Lilly and Company $46,062.00 01/07/2025 Non-covered Recipient Entity
EZY MEDICAL RESEARCH CO
PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 No dispute reported 06/30/2026 1187880067
Principal investigator 1 Eli Lilly and Company $151,418.00 01/07/2025 Non-covered Recipient Entity
EZY MEDICAL RESEARCH CO
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF GALCANEZUMAB IN PATIENTS 6 TO 17 YEARS OF AGE WITH EPISODIC MIGRAINE - THE REBUILD STUDY No dispute reported 06/30/2026 1187881158
Principal investigator 1 Eli Lilly and Company $20,421.00 01/07/2025 Non-covered Recipient Entity
EZY MEDICAL RESEARCH CO
A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF GALCANEZUMAB IN ADOLESCENT PATIENTS 12 TO 17 YEARS OF AGE WITH CHRONIC MIGRAINE THE REBUILD 2 STUDY No dispute reported 06/30/2026 1187882930